Biomea Fusion, Inc. (BMEA) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

51NeutralDD: Jul 13, 2026Analyst: 47

paidPrice at analysis date

USD 1.32 (13/07/2026)

domainMkt cap

$95.4M

pie_chartShares

72.3M

candlestick_chart52W

$0.87-$3.08

trending_downShort interest

19.5%

MEDIUMNasdaq Global Select MarketHealth Care40 employeesFounded 2017

Verdict: Caution —

Speculative biotech with going-concern flag but multiple binary catalysts H2 2026 (BMF-650 obesity 28-day Q3, COVALENT-211/212 T2D 26-week Q4). Positive 52-week icovamenib data at ATTD/ADA validates menin-inhibitor thesis in severe insulin-deficient T2D and GLP-1 non-responders. Market cap $95M leaves rNPV asymmetry to the upside if catalysts land, but downside floor is cash ($45M) minus expected dilution — narrative equity in binary regime. Not suitable for concentrated positions.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-13

Biomea Fusion, Inc. (BMEA)

Clinical-stage Biotech · NASDAQ · San Carlos, CA

"Speculative Ph 2 biotech — asymmetric R/R gated by H2 2026 readouts, funded only to Q1 2027."

52W Ph2 data positive Q3/Q4 catalysts loaded Going concern flag SI 19.5% — very high Class action active

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — rNPV probability-weighted pipeline + cash floor − dilution

Fair value base case

USD 1.85

Range: USD 0.50-USD 4.20

Price at analysis date: USD 1.32 (13/07/2026)

Base upside/downside: +40%

Per-asset rNPV with explicit PoS assumptions (25%/15%/10% for icovamenib T2D/T1D/BMF-650), cash floor at book value, dilution modeled as $40M raise at $1.50/sh (base case). Implied per-asset value at market: only ~$0.77/sh across pipeline vs our summed rNPV of $2.38/sh pre-dilution (net $1.31/sh post-dilution). Cross-check EV/cash 1.3x vs peer 0.7x avg = market prices +85% pipeline premium consistent with our BMF-650 rNPV of $0.69/sh. Consensus PT $6.50 diverges materially (>3x our FV); consensus implicitly assumes higher PoS and/or no dilution — legitimate but optimistic. Recommend anchoring on our range $0.50-$4.20 rather than point estimate. Sensitivity: +2x PoS on icovamenib T2D → FV $3.80 (+29% vs base). ⚠️ Not investment advice.

Component	Assumption	USD/share
Icovamenib T2D (rNPV)	25% PoS × $400M peak NPV (severe insulin-deficient + GLP-1 non-responders niche) / 72.3M shares	+1.38
Icovamenib T1D (rNPV)	15% PoS × $150M NPV (C-peptide improvement niche) / 72.3M shares	+0.31
BMF-650 oral GLP-1 (rNPV)	10% PoS × $500M NPV (obesity — Ph 1 early, competes with mature GLP-1 class) / 72.3M shares	+0.69
Net cash floor	($45.1M cash − $6M debt) / 72.3M shares	+0.54
Expected dilution (H2 2026)	$40M raise @ ~$1.50 = 26.7M new shares (+37% dilution); haircut on FV pre-dilution	−1.07
FV base case	Sum (1.38 + 0.31 + 0.69 + 0.54 − 1.07)	≈ $1.85

Bull

$3.50–4.20

Probability: 20%

Both Q3 BMF-650 obesity 28-day data AND Q4 COVALENT-211/212 T2D 26-week data positive. PoS re-rates to 40% on icovamenib, 25% on BMF-650. Financing at $3-4 dilutes less. Consensus PT $6.50 partially realizable.

Base

$1.50–2.20

Probability: 45%

Mixed catalyst outcomes: one positive, one equivocal. PoS stable at 20-25%. $40M ATM raise executes Q4 2026 near current price → 30-40% dilution.

Bear

$0.50–0.90

Probability: 35%

One or both Q3/Q4 readouts miss or generate safety signal. FDA hold precedent (BMF-219 2024) re-emerges. Emergency dilution at $0.80-1.00, cash floor becomes ceiling.

Methodology: Per-asset rNPV with explicit PoS assumptions (25%/15%/10% for icovamenib T2D/T1D/BMF-650), cash floor at book value, dilution modeled as $40M raise at $1.50/sh (base case). Implied per-asset value at market: only ~$0.77/sh across pipeline vs our summed rNPV of $2.38/sh pre-dilution (net $1.31/sh post-dilution). Cross-check EV/cash 1.3x vs peer 0.7x avg = market prices +85% pipeline premium consistent with our BMF-650 rNPV of $0.69/sh. Consensus PT $6.50 diverges materially (>3x our FV); consensus implicitly assumes higher PoS and/or no dilution — legitimate but optimistic. Recommend anchoring on our range $0.50-$4.20 rather than point estimate. Sensitivity: +2x PoS on icovamenib T2D → FV $3.80 (+29% vs base). ⚠️ Not investment advice. Not investment advice.

warning

🚨 Going-concern qualification + active class action

Q1 2026 10-Q flags "substantial doubt" about ability to continue as going concern without additional financing (cash $45.1M runway into Q1 2027, quarterly burn ~$12M and falling). Multiple securities-fraud class action investigations open (Rosen Law, Bronstein Gewirtz Grossman, Gross Law Firm) stemming from 2024-06-06 FDA full clinical hold on BMF-219, when the stock dropped 63% intraday. Active S-3 shelf registration + prior ATM takedowns mean equity raise is a near-certainty before Q1 2027.

⚠️ Methodology note: Pre-revenue clinical-stage biotech — valuation uses rNPV probability-weighted per-asset with cash floor as anchor, cross-checked with EV/pipeline stage vs biotech peers. No revenue multiples (revenue = $0 TTM). No EV/EBITDA (deeply negative). Multi-BU decomposition replaced by pipeline-asset decomposition. Expected dilution modeled explicitly as a negative FV component.

📊 Capital Structure · Short Interest · Buyback & Dilution

🔴 Short Interest

19.5%

~14.09M shares short vs 72.30M outstanding. "Very high" range (>15%). Reflects going-concern skepticism + dilution expectation. Squeeze risk if BMF-650 Q3 data positive: days-to-cover ~10 given ~1.4M ADV.

🔴 Share dilution (1Y)

+~15%

From ~63M shares to 72.3M — driven by 2 ATM/424B5 takedowns in Oct 2025 and executive stock option grants. Active S-3 shelf enables further raises. Expected +30-40% additional dilution over next 12 months to bridge runway.

🔴 Buyback

Zero. Pre-revenue biotech with cash constraint — cannot deploy capital to buyback. Capital priority: pipeline funding + runway extension via ATM/shelf.

Short Interest — context

BMEA — 19.5%

19.5%

Insider activity last 12M (Form 4): Rainer M. Erdtmann (director/officer) received grant of 1,246,989 stock options at $1.53 strike on 2025-08-11 (~$1.9M implied value at strike). Director grants of 196,299 stock options. One small insider buy of 30,000 shares. No insider selling >$500K threshold identified. Institutional ownership 48.39%: top holders Fidelity/Fmr LLC, Cormorant Asset Management, BlackRock, Vanguard, Aisling Capital.

$Financial analysis — FY2025 & 1Q26

Cash (Q1 26)

$45.1M

Runway into Q1 2027

Net loss (Q1 26)

−$12.4M

vs −$29.3M Q1'25

EPS Q1'26 (non-GAAP)

−$0.17

Beat −$0.24 consensus

Enterprise Value

$58.9M

EV/cash 1.3x

Item	FY2023	FY2024	FY2025	FY2026E	Guidance
Revenue ($M)	0	0	0	0	Pre-revenue
R&D expense ($M)	~95	~120	~85	~55	Cost cuts H2'25
Net loss ($M)	−105	−140	−95.7	−55	Burn narrowing
Diluted EPS ($)	−2.85	−3.40	−2.25	−0.80	−$0.68 TTM
Cash EOP ($M)	135	80	58	15–25	Q1 2027 runway limit
Shares out (M)	37	41	63	95+	ATM active
Book value/sh ($)	2.90	1.20	0.55	0.42	Ph 2 costs

FY2024 includes non-recurring charges related to BMF-219 program discontinuation and FDA hold response. FY2026E based on Q1 annualized + guidance color; assumes $40M raise Q4 2026.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	0.0	0.0	0.0	0.0	0.0
R&D expense ($M)	25.0	22.0	19.0	19.0	10.5
Net loss ($M)	−29.3	−26.5	−22.0	−17.9	−12.4
EPS (GAAP $)	−0.72	−0.62	−0.42	−0.32	−0.19
Cash EOP ($M)	90	72	67	58	45.1

Financial position and sustainability

Cash runway (months)

~10 mos

Burn rate reduction (YoY)

−58%

Pipeline diversification

2 assets

Short interest (% float)

19.5%

Insider ownership

9.47%

account_tree

Business model — Menin inhibitor + oral GLP-1 pipeline

Two-asset clinical-stage platform in metabolic disease

Biomea Fusion is a clinical-stage biotech developing oral covalent small-molecule drugs for diabetes and obesity. Lead asset icovamenib is a covalent menin inhibitor — menin is a scaffold protein involved in beta-cell regeneration and function, with the therapeutic hypothesis that inhibiting menin can restore beta-cell mass/function in T2D (particularly severe insulin-deficient sub-populations) and preserve residual insulin production in T1D. Second asset BMF-650 (formerly disclosed as GLP-131 clinical program) is an oral GLP-1 receptor agonist entering the massive obesity market currently dominated by Novo Nordisk (semaglutide/Wegovy) and Eli Lilly (tirzepatide/Zepbound). Company pivoted focus following 2024 FDA hold on a prior menin candidate (BMF-219); icovamenib is a distinct clinical entity that has cleared chronic toxicology studies and is advancing to 26-week and extended (6-12 month) dosing trials.

Icovamenib T2D (COVALENT-111/211/212) rNPV ~$100M (25% PoS × $400M) 🟢 Ph 2 readouts Q4 2026 Menin inhibitor for Type 2 Diabetes. 52-week Ph 2 data at ATTD Mar 2026: 1.2% HbA1c reduction in severe insulin-deficient patients, 1.3% in GLP-1 non-responders (p=0.05, n=11). COVALENT-211/212 dosing first patients, topline 26-week Q4 2026. Icovamenib T1D (COVALENT-112) rNPV ~$22M (15% PoS × $150M) 🟡 Ph 2 exploratory Type 1 Diabetes: 12-week icovamenib treatment. 52-week C-peptide improvement + durability supports mechanism-of-action for beta-cell preservation. Smaller commercial opportunity vs T2D but rare-disease pricing dynamics. BMF-650 oral GLP-1 (Obesity) rNPV ~$50M (10% PoS × $500M) 🟡 Ph 1 · 28-day data Q3'26 Oral GLP-1 receptor agonist for weight loss. Phase I GLP-131 trial. Initial 28-day weight-reduction data now expected Q3 2026 (delayed from Q2 for additional dose cohort). Competes with mature GLP-1 class but oral formulation is differentiator.

gavel

Legal, regulatory and risk analysis

Going-concern qualification

Critical

Q1 2026 10-Q flags "substantial doubt" — cash $45.1M runway only into Q1 2027 at current burn (~$12M/qtr and falling). Company must raise $30-40M+ within 6-9 months to sustain operations through Ph 3 planning. If catalysts miss, financing at $0.50-0.80 becomes distressed.

Active class action investigations

High

Rosen Law, Bronstein Gewirtz Grossman, Gross Law Firm all investigating securities-fraud claims tied to 2024-06-06 FDA full clinical hold on BMF-219. Stock fell 63% intraday. Class period predates icovamenib clinical progress but legal overhang remains and could result in settlement drag on cash.

Dilution risk — active shelf & ATM

High

Active S-3 shelf up to $350M capacity, 2 prior ATM takedowns in Oct 2025. Expected $40M raise Q4 2026 = ~27M new shares at $1.50 = +37% dilution. If pre-empted by positive Q3 obesity data, dilution at higher price is accretive vs base case.

FDA regulatory precedent (2024 BMF-219 hold)

High

Prior FDA full clinical hold on menin inhibitor BMF-219 in June 2024 (safety signal, later lifted). Precedent creates heightened scrutiny on icovamenib safety profile as chronic dosing (6-12 months) begins H2 2026. Any recurrence would trigger another 40-60% price shock.

Competitive intensity (GLP-1 space)

Moderate

BMF-650 enters obesity market dominated by Novo/Lilly with entrenched injectable GLP-1s and pipeline of oral GLP-1s (Novo's orforglipron, Lilly's oral semaglutide, Structure Therapeutics GSBR-1290, Terns oral GIPR/GLP-1). Differentiation depends on tolerability, efficacy, and dosing convenience. Ph 1 stage means 5-6 years to market vs entrenched leaders.

Multiple binary Q3/Q4 catalysts

Positive

BMF-650 28-day obesity data Q3 2026 + COVALENT-211/212 26-week T2D data Q4 2026 = two independent binary events within 6 months. Positive combination = base case fair value pathway. Combined with 19.5% short interest, positive outcome could trigger technical squeeze.

Burn rate reduction (execution)

Positive

Quarterly net loss narrowed from $29.3M (Q1'25) to $12.4M (Q1'26) — 58% reduction YoY. Q1 EPS beat consensus by $0.07. Signals management is managing runway carefully, extending timeline to catalyst delivery.

Menin inhibitor mechanism validation

Positive

52-week Ph 2 data shows durable HbA1c reduction in specific sub-populations (severe insulin-deficient + GLP-1 non-responders) that current standard-of-care fails. Mechanism (beta-cell regeneration) is scientifically distinctive vs GLP-1 satiety mechanism — potential combination therapy narrative supports peak sales assumption.

article

SWOT analysis

Strengths

+Positive 52-week Ph 2 icovamenib data (1.2-1.3% HbA1c reduction in T2D niches)
+Two independent binary catalysts Q3-Q4 2026 (obesity + T2D)
+Q1 2026 EPS beat consensus by $0.07 with 58% YoY burn reduction
+Distinct mechanism (menin/beta-cell) vs GLP-1 class → combination therapy narrative
+Chronic toxicology cleared for icovamenib (enables 6-12 month dosing)

Weaknesses

−Going-concern qualification in Q1 2026 10-Q
−Cash runway only into Q1 2027 → forced financing pre-Q4 catalysts
−Pre-revenue, deeply negative EBITDA and ROE (−209%)
−Active class action from 2024 FDA hold on BMF-219
−Small team (42 employees) limits execution bandwidth

Opportunities

→Global diabetes market: 500M+ patients, standard-of-care limitations for severe insulin-deficient
→Global obesity market: expected $150B by 2030, oral GLP-1 differentiation
→Partnership / licensing deal with Big Pharma (Novo/Lilly) as validation event
→19.5% short interest → potential squeeze if Q3 obesity data positive
→FDA Type C meeting on Ph 3 design could de-risk regulatory pathway

Threats

!Recurring FDA safety hold (precedent from 2024) triggering 40-60% drawdown
!Negative Q3 BMF-650 obesity data → cash-only valuation ($0.50 floor)
!Novo Nordisk / Lilly pipeline competition in oral GLP-1 space
!Distressed financing at $0.80 if catalysts underwhelm
!Class action settlement drag on limited cash

article

Summary by assessment area

🔴 Financial Sustainability — Fragile

Going-concern flag active, runway into Q1 2027 only
Must raise $30-40M+ within 6-9 months
Burn narrowing but not enough to escape dilution
Score 10/35 pts on Fin/EBITDA combined

🟢 Catalyst Density — Very High

Q3 2026: BMF-650 obesity 28-day weight-reduction data
Q4 2026: COVALENT-211/212 T2D 26-week readout
H2 2026: extended dosing Ph 2 initiation
Score 8/10 pts on Catalysts — best category

🟡 Risk/Reward — Asymmetric Bull

Downside floor at cash ($0.50/sh net of dilution)
Base FV +40% vs current $1.32
Bull scenario +170% to $3.50-4.20 if both catalysts positive
Binary regime — position sizing critical

2026-09-30 product

BMF-650 GLP-131 Ph 1 28-day weight-reduction readout

short-term Impact: High Direction: Binary

First clinical evidence of oral GLP-1 candidate. Weight-reduction magnitude vs semaglutide/tirzepatide benchmark will determine whether BMF-650 is competitive. Positive = major re-rating catalyst; negative = pipeline value collapses to icovamenib alone.

2026-08-13 earnings

Q2 2026 Earnings — burn rate & runway update

short-term Impact: Medium Direction: Neutral

Confirms burn trajectory and any financing activity in Q2. Watch for updated runway guidance (currently "into Q1 2027") and any ATM utilization disclosure.

2026-12-15 product

COVALENT-211/212 Ph 2 T2D 26-week topline

medium-term Impact: High Direction: Binary

Confirmation of 52-week ATTD signal in larger patient population. Positive = enables FDA Type C meeting on Ph 3 design + partnership discussions. Negative = icovamenib rNPV collapses.

2026-11-15 capital_markets

Equity raise via S-3 shelf / ATM (estimated $40M)

short-term Impact: High Direction: Bearish

Financing likely to occur between Q3 obesity data and Q4 T2D data (window of higher share price after positive catalyst). If executed at $2+, less dilutive; if at $1, materially dilutive (+40% share count).

2026-10-31 operational

Icovamenib 6-12 month extended dosing Ph 2 initiation

medium-term Impact: Medium Direction: Bullish

Chronic toxicology cleared enables extended dosing. First-patient-dosed announcement de-risks safety concerns and sets stage for Ph 3 program design. Leading academic centers as sites adds credibility.

2026-09-15 regulatory

Lead plaintiff deadline in ongoing class action

short-term Impact: Low Direction: Bearish

Rosen Law and Bronstein Gewirtz investigations may consolidate. Settlement drag potential over next 12-18 months but limited relative to catalyst impact.

2026-12-31 partnership

Icovamenib licensing/partnership optionality

medium-term Impact: High Direction: Bullish

Positive 26-week T2D data + BMF-650 combination narrative could attract Novo Nordisk, Lilly, or Sanofi as partner. Even option deal ($100M upfront + milestones) would transform valuation.

{ "verdict_label": {"it": "Giudizio: Cautela", "en": "Verdict: Caution"}, "verdict_text": {"it": "Biotech Ph2 speculativo con going-concern flag ma catalizzatori binari Q3/Q4 2026 su obesita' e diabete. Asimmetria interessante ma binaria — non adatta a posizioni concentrate.", "en": "Speculative Ph 2 biotech with going-concern flag but binary Q3/Q4 2026 catalysts on obesity and diabetes. Interesting asymmetry but binary — not suitable for concentrated positions."}, "bull_points": [ {"it": "Dati Ph2 52-settimane icovamenib positivi (HbA1c -1.2/-1.3% in nicchie T2D)", "en": "Positive 52-week Ph 2 icovamenib data (HbA1c -1.2/-1.3% in T2D niches)"}, {"it": "Due catalizzatori binari indipendenti H2 2026: BMF-650 obesita' Q3 + T2D Q4", "en": "Two independent binary catalysts H2 2026: BMF-650 obesity Q3 + T2D Q4"}, {"it": "Short interest 19.5% + burn -58% YoY: squeeze potential se dati positivi", "en": "Short interest 19.5% + burn -58% YoY: squeeze potential if data positive"} ], "bear_points": [ {"it": "Going concern qualification: liquidita' solo fino Q1 2027 senza nuovo finanziamento", "en": "Going concern qualification: cash runway only into Q1 2027 without new financing"}, {"it": "Diluzione attesa 30-40% da ATM/shelf per estendere runway", "en": "Expected 30-40% dilution from ATM/shelf to extend runway"}, {"it": "Precedente FDA clinical hold 2024 su BMF-219 + class action attive", "en": "2024 FDA clinical hold precedent on BMF-219 + active class action lawsuits"} ], "risks": [ {"it": "Dati negativi obesita' Q3 → valutazione collassa a floor cash ($0.50/sh)", "en": "Negative Q3 obesity data → valuation collapses to cash floor ($0.50/sh)"}, {"it": "Financing distressato a $0.80 se catalizzatori mancano", "en": "Distressed financing at $0.80 if catalysts miss"}, {"it": "Competizione GLP-1 orale intensa (Novo, Lilly, Structure, Terns) rende BMF-650 tardivo", "en": "Intense oral GLP-1 competition (Novo, Lilly, Structure, Terns) makes BMF-650 a late entrant"} ] }

Sources & Disclaimer

Sources: MarketBeat (price history, short interest, analyst PT), Yahoo Finance, StockTitan (SEC filings 8-K/10-Q/Form 4), stocktitan.net (Q1 2026 press release, ADA/ATTD data), globenewswire (ADA 2026 presentations), Biomea Fusion investor relations (10-Q), Rosen Law / Bronstein Gewirtz Grossman / Gross Law Firm (class action notices), Fintel.io (institutional ownership), SEC Edgar (Form 4 filings). Market data — last verified close 2026-07-10: BMEA close $1.32, market cap ~$95.4M, 52W range $0.87–$3.08, ~72.3M shares outstanding, short interest ~19.5%. Q2 2026 earnings expected mid-August. This document is for informational purposes only and does not constitute financial or investment advice. ⚠️ Not investment advice.